Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
NCT00621673
·
clinicaltrials.gov ↗
PHASE4
Phase
TERMINATED
Status
1
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia A
Interventions
DRUG:
Kogenate (BAY 14-2222)
Sponsor
Bayer